3 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 3 of 3 clinical reviews.
A guide to lemborexant (Dayvigo) food and supplement interactions, covering grapefruit, alcohol, melatonin, valerian, and CYP3A4 inhibitors, with PubMed-cited evidence and dosing guidance.
Yes, Dayvigo (lemborexant) is a Schedule IV controlled substance. See why, plus its boxed warning, approved doses, and key FDA safety signals.
Dayvigo (lemborexant) is not approved by the UK's MHRA or EU's EMA as of mid-2024, though it holds FDA and Health Canada approval. See full status details.